New obesity drug put to the heart safety test
NCT ID NCT07229157
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is checking whether maridebart cafraglutide, a new weight-loss drug, affects the heart's electrical activity. About 81 adults with overweight or obesity will receive the drug or a placebo, and their heart rhythms will be closely monitored. The main goal is safety, not weight loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
maridebart cafraglutide (AMG 133)
What this could lead to
If successful, this study could show that maridebart cafraglutide is safe for the heart, supporting its development as a weight-loss treatment.
What could go wrong
This is a very early Phase 1 safety study with only 81 people. It is not designed to test weight loss, and the drug may still fail in later trials or have other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247-4968, United States
-
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, 32117-5116, United States